21 CFR 801 Medical Device Labeling Requirements: What You Must Get Right Before FDA Review

Why Labeling Is the First Place FDA Looks—and Where Many Devices Fail

Medical device labeling is not a packaging afterthought. It is a regulated, legally binding communication between your device and its users—and FDA reviewers scrutinize it closely. Deficiencies in labeling are among the most common reasons 510(k) submissions receive Additional Information (AI) requests, and noncompliant labeling in the field can trigger Warning Letters, import alerts, or recalls.

If you are a startup founder preparing your first submission, or a VP of Regulatory at a growing device company, understanding the requirements under 21 CFR Part 801 is not optional—it is foundational. This post breaks down what FDA requires, where companies most commonly fall short, and how to build labeling that passes review the first time.

What Counts as Labeling Under FDA's Definition

Most people think of labeling as the physical label affixed to the device or its packaging. FDA defines it far more broadly. Under 21 CFR 801.1 and the Federal Food, Drug, and Cosmetic Act (FD&C Act) Section 201(m), labeling includes all labels and other written, printed, or graphic matter that accompanies the device. This means your Instructions for Use (IFU), quick reference guides, promotional brochures, website content used in promotion, and even sales training materials may all constitute labeling subject to FDA oversight.

This distinction matters enormously. Claims you make in a brochure that exceed your cleared or approved indications can expose you to misbranding liability under 21 CFR 801.4, even if your physical device label is perfectly compliant.

Required Elements Under 21 CFR Part 801

The core labeling requirements that apply to virtually all medical devices include the following elements, each with its own regulatory basis:

• Name and place of business of the manufacturer, packer, or distributor — required under 21 CFR 801.1. This must be accurate and reflect the entity responsible for the device as it enters commerce.
• Intended use and indications for use — must be consistent with your cleared or approved submission. Any deviation constitutes a new intended use requiring a new submission per 21 CFR 807.81(a)(3).
• Adequate directions for use — under 21 CFR 801.5, directions must be written for the layperson unless an exemption applies. Most prescription devices qualify for the prescription exemption under 21 CFR 801.109, but meeting that exemption has its own conditions, including the Rx-only statement.
• Warnings, precautions, and contraindications — required to the extent necessary to protect user and patient safety. These must be prominent and conspicuous per 21 CFR 801.15.
• Lot or batch number, model number, catalog number, or serial number — required for traceability, and now intersects with the Unique Device Identification (UDI) requirements under 21 CFR Part 830 and 21 CFR 801.20.

UDI: A Labeling Requirement Many Startups Underestimate

The Unique Device Identification system is fully phased in, and compliance is not optional. Under 21 CFR 801.20, the label of a device must include a UDI, and that UDI must be submitted to FDA's Global Unique Device Identification Database (GUDID) via the AccessGDUD system. The UDI must appear in both human-readable interpretation (HRI) and machine-readable form (barcode or RFID), with specific exceptions for very small devices.

Class II devices were required to comply by September 2018, and Class I devices by September 2022. If your device is not UDI-compliant, you are already out of compliance and potentially subject to enforcement action.

Special Labeling Considerations by Device Type

Certain device categories carry additional labeling obligations beyond the baseline requirements of Part 801. In vitro diagnostic devices must comply with 21 CFR Part 809, which mandates specific performance characteristics, limitations, and quality control information. Radiation-emitting electronic products are subject to additional requirements under 21 CFR Part 1010. Devices marketed for over-the-counter use must meet the more stringent adequate directions for use standard without relying on the prescription exemption.

For Software as a Medical Device (SaMD), FDA's 2023 guidance on Predetermined Change Control Plans and the general wellness and clinical decision support frameworks also affect what claims can and cannot appear in labeling. If your software product sits near the boundary of device jurisdiction, labeling is often where FDA draws the line.

Common Labeling Mistakes That Delay Submissions

• Indications language in the IFU that does not match the indications submitted in the 510(k) or PMA
• Missing or improperly formatted Rx-only statement on prescription devices
• Failure to include a UDI or submitting an improperly structured Device Identifier
• Overly broad contraindications that conflict with the intended population
• Promotional claims embedded in the IFU that expand the cleared intended use
• Non-compliant symbol usage without reference to ISO 15223-1 or ANSI/AAMI standards as required by 21 CFR 801.15(c)(2)

Building a Labeling Review Process That Holds Up

Effective labeling compliance is not a one-time exercise—it is a controlled document process. Your labeling should be subject to design control under 21 CFR 820.30 (or ISO 13485 Section 7.3 if you operate under that framework), with version-controlled documents, cross-functional review, and a formal approval process before any labeling enters production or distribution. Any post-market labeling change must be evaluated against your change assessment procedures to determine whether it constitutes a submission-required change.

FDA's guidance document Labeling Recommendations for Single-Use Devices (2000) and the more recent Writing IFU for Small Volume Labeling guidance provide practical benchmarks that reviewers use—and so should your team.

Get Your Labeling Right Before It Costs You

Labeling errors do not just delay submissions—they can derail product launches, trigger inspectional findings, and create liability exposure long after a device reaches the market. Whether you are drafting your first IFU, preparing labeling for a 510(k) package, or conducting a post-market compliance audit, the details in 21 CFR Part 801 are non-negotiable.

At ADB Consulting & CRO Inc., we help medical device companies build labeling that is accurate, compliant, and submission-ready—the first time. Andre Butler and our regulatory team bring hands-on FDA submission experience to every engagement, from startup founders preparing their first 510(k) to established companies managing complex post-market labeling changes.

Book a free discovery call today at adbccro.com and find out exactly where your labeling stands—before FDA does.